Neurological Disorders by the Numbers
1 Billion
$1.6 Trillion
6.8 Million
People with Neurological
Disorders Globally
6.8 Million
$1.6 Trillion
6.8 Million
Deaths from Neurological
Disorders each Year
$1.6 Trillion
$1.6 Trillion
$1.6 Trillion
Combined Economic Burden in Europe and the USA alone
The PROBLEM
Lack of Biomarkers
Most brain disorders lack a biomarker (i.e, a way to measure disease progression). As a result, clinicians rely on subjective scales to measure efficacy of treatment which typically result in increased costs, poor patient outcomes, and years of time spent trying to find the right treatment.
Increased Costs while outcomes stagnant
A recent study showed that in the USA, direct costs related to Epilepsy have almost doubled in the last decade to $28B per year, while outcomes have not improved in almost three decades.
The Potential Benefits
Improving Outcomes
Improving Quality of Life
Improving Quality of Life
By helping clinicians get the data they need to identify the right treatments sooner.
Improving Quality of Life
Improving Quality of Life
Improving Quality of Life
Relieving patients and caregivers from the burden of self-reporting.
Reducing Costs
Improving Quality of Life
Reducing Costs
Reduce the number of costly visits to the hospital.
The Evidence
Proof of Concept: Completed
We completed a 30 patient proof-of-concept study which demonstrated that eye-tracking could be used to detect the subtlest seizure type, absence seizures.
DASEY Study (Ictal): Completed
Detecting Absence Seizures using Eye-tracking (DASEY): We have completed an in-depth clinical study supported by an NIH Phase 1 SBIR Grant involving 4 Level 4 Epilepsy Centers to analyze ictal eye-movement data and develop algorithms.
DASEY Study (Interictal): Completed
Supported by an NSF Phase 1 SBIR Grant we analyzed interictal eye-movement data and were able to show a correlation to subjects having active seizures.
DASHER Study: Enrolling
We have been awarded an NIH SBIR Phase I grant to compare the accuracy of 3 epileptologists reading a smartphone video recording during hyperventilation to 3 epileptologists reading the corresponding video EEG during hyperventilation. We are currently recruiting for this study. More information can be found here.
ACER Study: Enrolling
We have been awarded an SBIR Phase II grant from the National Science Foundation (NSF) for assessing comorbidities (e.g. attention and mood) in epilepsy using eye movement recordings. We are currently recruiting for this study. More information can be found here.
Our Team
Rachel Kuperman, MD, Founder & CEO
Parth Amin, Co-Founder and COO
Parth Amin, Co-Founder and COO
Neurologist with dual certification in epilepsy and neurology with over 10 years’ experience directing the clinical epilepsy and research programs at UCSF Benioff Children’s Hospital, Oakland
Parth Amin, Co-Founder and COO
Parth Amin, Co-Founder and COO
Parth Amin, Co-Founder and COO
Leads our Product Development efforts and GTM Strategy. Brings 15+ Years Medical Device Experience in Product and Project Management, Product Launch, and Alliances having worked at Siemens Healthineers, Varian, and Omnicell.
Jit Sarkar, PhD, Co-Founder and CTO
Parth Amin, Co-Founder and COO
Jit Sarkar, PhD, Co-Founder and CTO
Leads our eye-tracking research efforts . He completed his undergraduate degree in computer science and has deep experience applying machine learning methods. His PhD from UCSD focused on extracting signals from a complex medium.
Nate Blanco, Phd, Data Scientist
Ying Yu, Phd, Data Science Fellow
Jit Sarkar, PhD, Co-Founder and CTO
Leads the design and implementation efforts for our eye-tracking data science experiements. Brings experience in research, statistical analysis, and computational modeling in the field of cognitive neurosicience —most recently as a postdoctoral researcher in the Cognitive Development Lab at the Ohio State University.
Ying Yu, Phd, Data Science Fellow
Ying Yu, Phd, Data Science Fellow
Ying Yu, Phd, Data Science Fellow
Supports the design and implementation of our eye-tracking data science experiments. Completed her Ph.D. from The Ohio State University in cognitive psychology, focusing on visual perception research with psychophysics and statistical modeling.
Sarah Derr, MSW, Product Commercialization Manager
Ying Yu, Phd, Data Science Fellow
Ying Yu, Phd, Data Science Fellow
Driving initial roll-out and deployment initiatives to help Eysz transition from Idea Market Fit to Product Market Fit. She brings 5 years experience as a social worker holding various roles in a clinical care setting. She is currently pursing a Masters of Management in Clinical Informatics at Duke University.
Clinical Advisors
Robert Fisher, MD, PhD
Nicolle Napier-Ionascu, PsyD
Hal Blumenfeld, MD, PhD
Maslah Saul MD Professor Neurology and Director of the Stanford Epilepsy Center
Hal Blumenfeld, MD, PhD
Nicolle Napier-Ionascu, PsyD
Hal Blumenfeld, MD, PhD
Mark Loughridge and Michele Williams Professor of Neurology and Director, Yale Clinical Neuroscience Imaging Center
Nicolle Napier-Ionascu, PsyD
Nicolle Napier-Ionascu, PsyD
Nicolle Napier-Ionascu, PsyD
Head Neuropsychologist, Epilepsy at UCSF Benioff Children’s Hospital Oakland
Kathryn B. Lalor, MD
Shilpa B. Reddy MD, MMHC
Nicolle Napier-Ionascu, PsyD
Assistant Professor, Pediatrics - Pediatric Neurology at University of Alabama, Birmingham
Shilpa B. Reddy MD, MMHC
Shilpa B. Reddy MD, MMHC
Shilpa B. Reddy MD, MMHC
Assistant Professor of Pediatrics -
Pediatric Neurology | Medical Director Pediatric Epilepsy Monitoring Unit | Section Head Pediatric Epilepsy, Vanderbilt University Medical Center
Rani Singh, MD
Shilpa B. Reddy MD, MMHC
Shilpa B. Reddy MD, MMHC
Associate Professor of Pediatrics - Pediatric Neurology | Assistant Division Director for Research, Pediatric Neurology, Atrium Health/Levine Children’s Hospital
Shifteh Sattar, M.D.
Shifteh Sattar, M.D.
Shifteh Sattar, M.D.
Clinical Professor - Department of Neurosciences at University of California, San Diego; Medical Director of the Comprehensive Epilepsy Center at Rady Children’s Hospital
Business Advisors
Peter Milford, PhD Technical Advisor
Keith La Plain, Commercialization Advisor
Tracey Fisher, MBA Go-To-Market Advisor
20+ years experience in R&D including eye-tracking software and hardware development. Previous CTO of Eyefluence, (acquired by Google)
Tracey Fisher, MBA Go-To-Market Advisor
Keith La Plain, Commercialization Advisor
Tracey Fisher, MBA Go-To-Market Advisor
20+ years experience in medical device go-to-market strategies. Currently Senior Director Marketing Americas at Varian Medical Systems, a Siemens Healthineers company.
Keith La Plain, Commercialization Advisor
Keith La Plain, Commercialization Advisor
Keith La Plain, Commercialization Advisor
20+ years experience in commercialization of software as medical devices. Previous Senior Director for M&A Integration at Varian Medical Systems (acquired by Siemens Healthineers)
Board of Directors
Randy Berholtz JD, MBA
Colin Lake (Board Observer)
Colin Lake (Board Observer)
20+ years experience in Executive Management and Board Management. Currently serves as a Partner for Ventac Partners and a Senior Advisor for Mesa Partners. He is also a parent of a child with epilepsy.
Colin Lake (Board Observer)
Colin Lake (Board Observer)
Colin Lake (Board Observer)
15+ years experience in Digital Health and Pharma. Currently Head of Digital Transformation Neurology at UCB Pharma, a global leader in the field of epilepsy research and medicine development.